Compare AU
Compare CURE vs. EMKT
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the VanEck MSCI Multifactor Em Markets Equity ETF (EMKT). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | EMKT | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 159 |
Median incremental investment | $619.50 | $1,028.59 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $3,425.50 |
Average age group | > 35 | > 35 |
Key Summary
CURE | EMKT | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | EMKT.AX was created on 2018-04-10 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The VanEck MSCI Multifactor Emerging Markets Equity ETF (EMKT.AX) invests in a diversified portfolio of emerging markets listed securities with the aim of providing investment returns, before fees and other costs, which track the performance of the MSCI Emerging Markets Diversified MultipleFactor Index (AUD) (EMKT.AX Index). |
Top 3 holdings | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) | Taiwan Semiconductor Manufacturing Co Ltd (7.87 %) HCL Technologies Ltd (2.63 %) Tencent Holdings Ltd (2.49 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Information Technology (58.97 %) Materials (12.51 %) Real Estate (10.87 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | India (23.86 %) Taiwan (23.66 %) China (21.17 %) |
Management fee | 0.45 % | 0.69 % |
Key Summary
CURE | EMKT | |
|---|---|---|
Issuer | Global X | VanEck |
Tracking index | S&P Biotechnology Select Industry | MSCI Emerging Markets Diversified Multiple-Factor Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.69 % |
Price | $49.94 | $26.35 |
Size | $38.065 million | $181.537 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 3.31 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 12/04/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | EMKT | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 159 |
Median incremental investment | $619.50 | $1,028.59 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $3,425.50 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | EMKT | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | EMKT |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |